Skip to main content
. 2021 Dec 23;7(1):100336. doi: 10.1016/j.esmoop.2021.100336

Figure 4.

Figure 4

Bar graph progression-free survival comparisons for the patients who received both chemotherapy (red bars, PFS1) and immunotherapy (blue bars, PFS2).

PFS2/PFS1 ratio >1.3 was observed in 10/15 (67%) patients.

PFS, progression-free survival.